Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | EXECUTIVE VICE PRESIDENT | May 10, 2024 | May 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date May 10, 2024 · Filed May 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 211,341 |
Ending reported balance
After 2024-05-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-05-10 · Exercise / conversion · Acquired 10,097 · Balance 221,438 Row 2 · 2024-05-10 · Sale · Disposed 10,097 · Balance 211,341 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.55 to $104.62, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.00 · Expires 2025-02-19 | Direct | 45,000 |
Reported balance
After 2024-05-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-05-10 · Exercise / conversion · Disposed 10,097 · Balance 45,000 F5: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Trust | 20,000 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 20,000 F2: Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Trust | 20,000 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 20,000 F2: Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 18,765 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 18,765 F3: Balance in the Abbott Laboratories Stock Retirement Trust as of May 10, 2024. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Daughter | 500 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 500 F4: The reporting person disclaims beneficial ownership of all securities held by his daughter. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.55 to $104.62, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust.
F3: Balance in the Abbott Laboratories Stock Retirement Trust as of May 10, 2024.
F4: The reporting person disclaims beneficial ownership of all securities held by his daughter.
F5: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 05, 2018 Filed Sep 7, 2018 21:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 12,300 | $22.39 | $275,420.37 |
DisclosureSEC source: 0001179110-18-011220 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 21:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 9,700 | $26.19 | $254,022.63 |
DisclosureSEC source: 0001179110-18-011220 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 12,800 | $0.00 Strike: $26.02 | $0.00 |
DisclosureSEC source: 0001179110-18-008227 · edgar.xml · derivative · entry 6 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 12,800 shares Expires 2019-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,613 | $63.02 | $542,791.26 |
DisclosureSEC source: 0001179110-18-008227 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,680 Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 12,800 | $26.02 | $332,992.00 |
DisclosureSEC source: 0001179110-18-008227 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,220 | $58.99 | $71,970.24 |
DisclosureSEC source: 0001179110-18-003304 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,493 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,654 | $60.55 | $160,699.70 |
DisclosureSEC source: 0001179110-18-003304 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,713 Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 110,146 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002534 · edgar.xml · derivative · entry 5 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,146 Underlying: Common shares · 110,146 shares Expires 2028-02-15 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 36,716 on 02/16/2019, 36,715 on 02/16/2020, and 36,715 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 20,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002534 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,367 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,742 | $45.46 | $170,111.32 |
DisclosureSEC source: 0001179110-17-003671 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,337 Read SEC document |
| February 23, 2017 Filed Feb 24, 2017 22:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 25,500 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001179110-17-003180 · edgar.xml · derivative · entry 6 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 25,500 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 23, 2017 Filed Feb 24, 2017 22:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 25,500 | $45.50 | $1,160,250.00 |
DisclosureSEC source: 0001179110-17-003180 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,079 Read SEC document |
| February 23, 2017 Filed Feb 24, 2017 22:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 25,500 | $26.70 | $680,781.15 |
DisclosureSEC source: 0001179110-17-003180 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 23:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 48,831 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002963 · edgar.xml · derivative · entry 5 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,831 Underlying: Common shares · 48,831 shares Expires 2027-02-16 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,277 on 2/17/2018, 16,277 on 2/17/2019, and 16,277 on 2/17/2020. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 23:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 7,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002963 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,079 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| July 25, 2016 Filed Jul 27, 2016 20:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 26,800 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0001179110-16-027940 · edgar.xml · derivative · entry 6 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 26,800 shares Expires 2017-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 25, 2016 Filed Jul 27, 2016 20:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 26,800 | $43.08 | $1,154,544.00 |
DisclosureSEC source: 0001179110-16-027940 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,019 Read SEC document |
| July 25, 2016 Filed Jul 27, 2016 20:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 26,800 | $25.25 | $676,595.48 |
DisclosureSEC source: 0001179110-16-027940 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 23:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $39.30 | $11,790.69 |
DisclosureSEC source: 0001179110-16-020719 · edgar.xml · nonDerivative · entry 4 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,019 Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 23:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $39.30 | $3,930.40 |
DisclosureSEC source: 0001179110-16-020719 · edgar.xml · nonDerivative · entry 3 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,319 Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 23:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 933 | $39.31 | $36,671.57 |
DisclosureSEC source: 0001179110-16-020719 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,419 Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 23:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,838 | $39.52 | $112,157.76 |
DisclosureSEC source: 0001179110-16-020719 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,352 Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 23:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 83,333 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-16-019930 · edgar.xml · derivative · entry 5 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,333 Underlying: Common shares · 83,333 shares Expires 2026-02-18 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,778 on 02/19/2017, 27,777 on 02/19/2018, and 27,778 on 02/19/2019. Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 23:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 9,505 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-019930 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,190 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| July 29, 2015 Filed Jul 30, 2015 21:51 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 26,000 | $0.00 Strike: $21.22 | $0.00 |
DisclosureSEC source: 0001179110-15-011567 · edgar.xml · derivative · entry 6 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 26,000 shares Expires 2016-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 29, 2015 Filed Jul 30, 2015 21:51 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 17,763 | $50.94 | $904,847.22 |
DisclosureSEC source: 0001179110-15-011567 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,685 Read SEC document |
| July 29, 2015 Filed Jul 30, 2015 21:51 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 26,000 | $21.22 | $551,704.40 |
DisclosureSEC source: 0001179110-15-011567 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2015 Filed Mar 3, 2015 22:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,922 | $47.61 | $139,116.42 |
DisclosureSEC source: 0001179110-15-004043 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,448 Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 23:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 55,097 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003338 · edgar.xml · derivative · entry 5 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,097 Underlying: Common shares · 55,097 shares Expires 2025-02-19 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,366 on 2/20/16, 18,365 on 2/20/17, and 18,366 on 2/20/18. Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 23:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 7,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003338 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,370 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 13, 2015 Filed Feb 17, 2015 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 10,542 | $0.00 Strike: $22.27 | $0.00 |
DisclosureSEC source: 0001179110-15-002654 · edgar.xml · derivative · entry 6 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 10,542 shares Expires 2015-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 13, 2015 Filed Feb 17, 2015 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,917 | $45.22 | $312,786.74 |
DisclosureSEC source: 0001179110-15-002654 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,551 Read SEC document |
| February 13, 2015 Filed Feb 17, 2015 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 10,542 | $22.27 | $234,738.71 |
DisclosureSEC source: 0001179110-15-002654 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 700 | $38.97 | $27,281.80 |
DisclosureSEC source: 0001179110-14-004305 · edgar.xml · nonDerivative · entry 3 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,926 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 713 | $38.97 | $27,786.32 |
DisclosureSEC source: 0001179110-14-004305 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,626 Read SEC document |
| February 28, 2014 Filed Mar 4, 2014 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,129 | $39.79 | $124,502.91 |
DisclosureSEC source: 0001179110-14-004305 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,339 Read SEC document |
| February 21, 2014 Filed Feb 25, 2014 22:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 44,325 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001179110-14-003627 · edgar.xml · derivative · entry 5 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,325 Underlying: Common shares · 44,325 shares Expires 2024-02-20 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,775 on 2/21/2015, 14,775 on 2/21/2016, and 14,775 on 2/21/2017. Read SEC document |
| February 21, 2014 Filed Feb 25, 2014 22:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 7,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-003627 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,468 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| January 31, 2014 Filed Feb 4, 2014 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,546 | $0.00 Strike: $35.08 | $0.00 |
DisclosureSEC source: 0001179110-14-001871 · edgar.xml · derivative · entry 12 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,546 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 31, 2014 Filed Feb 4, 2014 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 5,715 | $0.00 Strike: $33.88 | $0.00 |
DisclosureSEC source: 0001179110-14-001871 · edgar.xml · derivative · entry 11 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 5,715 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 31, 2014 Filed Feb 4, 2014 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,137 | $0.00 Strike: $31.61 | $0.00 |
DisclosureSEC source: 0001179110-14-001871 · edgar.xml · derivative · entry 10 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 2,137 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 31, 2014 Filed Feb 4, 2014 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,192 | $36.21 | $43,162.32 |
DisclosureSEC source: 0001179110-14-001871 · edgar.xml · nonDerivative · entry 6 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,228 Read SEC document |
| January 31, 2014 Filed Feb 4, 2014 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,608 | $36.20 | $203,009.60 |
DisclosureSEC source: 0001179110-14-001871 · edgar.xml · nonDerivative · entry 5 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,420 Read SEC document |
| January 31, 2014 Filed Feb 4, 2014 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,598 | $36.19 | $94,021.62 |
DisclosureSEC source: 0001179110-14-001871 · edgar.xml · nonDerivative · entry 4 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,028 Read SEC document |
| January 31, 2014 Filed Feb 4, 2014 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,546 | $35.08 | $54,233.68 |
DisclosureSEC source: 0001179110-14-001871 · edgar.xml · nonDerivative · entry 3 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2014 Filed Feb 4, 2014 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 5,715 | $33.88 | $193,624.20 |
DisclosureSEC source: 0001179110-14-001871 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2014 Filed Feb 4, 2014 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,137 | $31.61 | $67,546.51 |
DisclosureSEC source: 0001179110-14-001871 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.